Fungal infection-related conditions and outcomes in severe COVID-19: a nationwide case-control study
In patients with severe COVID-19 requiring MV, each additional day of steroid use was associated with prolonged use of antifungal medications for ≥ 5 days.
Authors
- Ryo Yamamoto (ORCID: https://orcid.org/0000-0001-8772-9600)
- Kazuki Matsumura (ORCID: https://orcid.org/0000-0001-9367-1636)
- Takashi Tagami (ORCID: https://orcid.org/0000-0001-6953-1932)
- Atsushi Hirayama (ORCID: https://orcid.org/0000-0002-6712-6930)
- Mineji Hayakawa (ORCID: https://orcid.org/0000-0001-8341-7626)
- Katsuya Maeshima (ORCID: https://orcid.org/0000-0002-0594-0873)
- Daiki Kaito (ORCID: https://orcid.org/0000-0001-6007-6769)
- Kazuma Yamakawa (ORCID: https://orcid.org/0000-0003-2999-4021)
- Junichi Sasaki (ORCID: https://orcid.org/0000-0002-5190-8524)
- Koichiro Homma (ORCID: https://orcid.org/0000-0001-5223-9599)
- Hideo Yasunaga (ORCID: https://orcid.org/0000-0002-6017-469X)
- Takayuki Ogura
Institutions
- Keio University (JP)
- Keio University Hospital (JP)
- University of Tokyo Health Sciences (JP)
- Saiseikai Utsunomiya hospital (JP)
- Hokkaido University Hospital (JP)
- Nippon Medical School (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s12879-024-10317-z
- Citations
- 2
- Primary Topic
- Antifungal resistance and susceptibility
- Type
- article
- Field-Weighted Citation Impact
- 0.78